{
    "Rank": 305,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT04835675",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "ZJYY-2020006"
                },
                "Organization": {
                    "OrgFullName": "Zhujiang Hospital",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Hepatobiliary Cancer Malignancies",
                "OfficialTitle": "Development and Validation of the Performance of a cfDNA Methylation-based Model Combined With Serum Tumor Markers for Early Hepatobiliary Malignancies Detection",
                "Acronym": "ASCEND-Hep"
            },
            "StatusModule": {
                "StatusVerifiedDate": "April 2021",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "March 12, 2021",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "March 31, 2022",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "June 30, 2022",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "April 6, 2021",
                "StudyFirstSubmitQCDate": "April 6, 2021",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "April 8, 2021",
                    "StudyFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "March 1, 2023",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "March 2, 2023",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Zhujiang Hospital",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "Guangzhou BR",
                            "CollaboratorClass": "UNKNOWN"
                        }
                    ]
                }
            },
            "OversightModule": {
                "IsFDARegulatedDrug": "No",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "This study is a prospective, multicenter study aimed to develop and validate the performance of combined assays for cfDNA methylation markers and serum tumor markers in early hepatobiliary malignancies detection. Circulating tumor DNA (ctDNA) mutation, blood RNA markers and tissue will also be evaluated. The study will enroll approximately 496 participants, including participants with malignant or benign diseases of the hepatobiliary system."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Hepatobiliary Malignancies"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Hepatobiliary malignancies",
                        "Liquid biopsy",
                        "Cell-free DNA",
                        "Early detection"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Observational",
                "PatientRegistry": "No",
                "DesignInfo": {
                    "DesignObservationalModelList": {
                        "DesignObservationalModel": [
                            "Case-Control"
                        ]
                    },
                    "DesignTimePerspectiveList": {
                        "DesignTimePerspective": [
                            "Prospective"
                        ]
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "496",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Cancer Arm",
                            "ArmGroupDescription": "Participants with new diagnosis of hepatobiliary malignancies, from whom blood samples will be collected",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Device: Multi-cancer early detection test"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "Benign Diseases Arm",
                            "ArmGroupDescription": "Participants with benign diseases of the hepatobiliary system, from whom blood samples will be collected",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Device: Multi-cancer early detection test"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Device",
                            "InterventionName": "Multi-cancer early detection test",
                            "InterventionDescription": "Blood collection and multi-cancer early detection testing",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Benign Diseases Arm",
                                    "Cancer Arm"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Sensitivity of early hepatobiliary malignancies detection and Tissue of origin (TOO) accuracy of a cfDNA methylation-based model combined with serum tumor markers when specificity was 90%, 95% or 98%",
                            "PrimaryOutcomeTimeFrame": "16 months"
                        },
                        {
                            "PrimaryOutcomeMeasure": "Sensitivity and specificity of early hepatobiliary malignancies detection and TOO accuracy of a cfDNA methylation-based model combined with serum tumor markers",
                            "PrimaryOutcomeTimeFrame": "16 months"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Sensitivity and specificity of a cfDNA methylation-based model combined with serum tumor markers in early detection of hepatobiliary malignancies in different stages",
                            "SecondaryOutcomeTimeFrame": "16 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Sensitivity and specificity of a cfDNA methylation-based model combined with serum tumor markers, clinical characteristics and other biomarkers",
                            "SecondaryOutcomeTimeFrame": "16 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Sensitivity and specificity of a cfDNA methylation-based model combined with serum tumor markers in participants with malignant or benign diseases of the hepatobiliary system",
                            "SecondaryOutcomeTimeFrame": "16 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Sensitivity and specificity of a cfDNA methylation-based model or serum tumor markers in participants with hepatobiliary malignancies",
                            "SecondaryOutcomeTimeFrame": "16 months"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria for All the Participants:\n\n40-75 years old\nAbility to comply with study procedures\nAbility to provide a written informed consent\n\nExclusion Criteria for All the Participants:\n\nPregnancy or lactating women\nRecipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant\nRecipients of blood transfusion within 7 days prior to study blood draw\nRecipients of anti-microbial therapy within 14 days prior to study blood draw\nRecipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer\n\nInclusion Criteria for Cancer Arm Participants:\n\nConfirmed diagnosis or highly suspicious cases of hepatobiliary malignancies\nNo prior or ongoing anti-cancer therapy (local or systematic) prior to study blood draw\n\nExclusion Criteria for Cancer Arm Participants:\n\nCurrent diagnosis of other malignancies or multiple primary tumors\nDiagnosis of benign diseases by histopathological assessments\nInability to characterize whether the lesion is malignant or benign\nPrior or ongoing treatment of cancer\n\nInclusion Criteria for Benign Diseases Arm Participants:\n\nConfirmed diagnosis of benign diseases of the hepatobiliary system\nNo prior radical treatment of the benign diseases prior to study blood draw\n\nExclusion Criteria for Benign Diseases Arm Participants:\n\nCurrent or history of malignancies or precancerous lesions\nNo confirmed diagnosis or inability to characterize a benign disease",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "40 Years",
                "MaximumAge": "75 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                },
                "StudyPopulation": "Eligible participants will be recruited from medical centers and assigned into two arms, including participants with new diagnosis of hepatobiliary malignancies and benign diseases of the hepatobiliary system.",
                "SamplingMethod": "Non-Probability Sample"
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Mingxin Pan",
                            "OverallOfficialAffiliation": "Zhujiang Hospital",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Zhujiang Hospital",
                            "LocationCity": "Guangzhou",
                            "LocationState": "Guangdong",
                            "LocationZip": "510280",
                            "LocationCountry": "China"
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "No"
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000009369",
                            "ConditionMeshTerm": "Neoplasms"
                        }
                    ]
                }
            }
        }
    }
}